Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Biogen’s $7.3 Bln acquisition of Reata followed bidding war

<< Previous

Bullboard Posts

Next >>

Comment by Buckhenryon Aug 17, 2023 7:14pm

149 Views

Post# 35593969

RE:RE:RE:RE:RE:RE:RE:RE:Biogen’s $7.3 Bln acquisition of Reata followed bidding war

I think many of us are just tired of reading the same Ole regurgitated rhetorical stuff that was posted years ago. There is just really not to much to say at this point that has not been said and everybody has known. Everyone is just guessing. That and 3 bucks will get you coffee at Starbucks. Remember. The beatings will continue until moral improves.

<< Previous

Bullboard Posts

Next >>

Stockhouse DealRoom opens new Australian opportunities